Kala Bio (KALA) Net Shares Issued and Repurchased (2016 - 2025)
Kala Bio's (KALA) quarterly Net Shares Issued and Repurchased came in at $689525.0 in Q4 2025, up 117.42% year-over-year from $317139.0 in Q4 2024, and up 7152.05% quarter-over-quarter from $9508.0 in Q1 2025.
Powered by 
Analysis
Kala Bio (KALA) Net Shares Issued and Repurchased (2016 - 2025) Analysis & Trends
Kala Bio has disclosed Net Shares Issued and Repurchased across 10 years of filings, most recently posting $689525.0 for Q4 2025.
- In Q4 2025, Net Shares Issued and Repurchased rose 117.42% year-over-year to $689525.0; the TTM figure through Dec 2025 stood at $689525.0 (up 117.42% YoY), while the FY2025 annual figure was $689525.0, up 117.42% from the prior year.
- Net Shares Issued and Repurchased came in at $689525.0 for Q4 2025 at Kala Bio, up from $9508.0 in the prior quarter.
- In the past five years, Net Shares Issued and Repurchased ranged from a high of $3.7 million in Q1 2022 to a low of $4200.0 in Q1 2023.
- Average Net Shares Issued and Repurchased over 5 years is $731434.5, with a median of $302415.0 recorded in 2024.
- Year-over-year, Net Shares Issued and Repurchased tumbled 99.89% in 2023 and surged 6749.79% in 2024.
- Over 5 years, Net Shares Issued and Repurchased stood at $44727.0 in 2021, then soared by 86.06% to $83221.0 in 2022, then surged by 701.43% to $666962.0 in 2023, then sank by 52.45% to $317139.0 in 2024, then jumped by 117.42% to $689525.0 in 2025.
- Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $689525.0 in Q4 2025, $9508.0 in Q1 2025, and $317139.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Kala Bio | 7.80 Mn | 7.80 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 689,525.00 |
| Mar 31, 2025 | 9,508.00 |
| Dec 31, 2024 | 317,139.00 |
| Mar 31, 2024 | 287,691.00 |
| Dec 31, 2023 | 666,962.00 |
| Mar 31, 2023 | 4,200.00 |
| Dec 31, 2022 | 83,221.00 |
| Mar 31, 2022 | 3.70 Mn |
| Dec 31, 2021 | 44,727.00 |
| Mar 31, 2021 | 1.51 Mn |
| Dec 31, 2020 | 1.82 Mn |
| Mar 31, 2020 | 1.47 Mn |
| Dec 31, 2019 | 2.64 Mn |
| Sep 30, 2019 | 27,000.00 |
| Jun 30, 2019 | 63,000.00 |
| Mar 31, 2019 | 791,170.00 |
| Dec 31, 2018 | 1.73 Mn |
| Sep 30, 2018 | 69,500.00 |
| Jun 30, 2018 | 150,000.00 |
| Dec 31, 2017 | 973,492.00 |